# KM05 Preference Label 1 - Transcript A vs B (workspace backup)

Stage: Step 15 Preference Labeling (Healthcare_247_Merrow - Task b0tza971, batch 20260609_045644).
Current status: DRAFT for platform entry.

Studio-selected pair:
- Transcript A = 0.680, 53 steps, 13m 33s.
- Transcript B = 0.350, 48 steps, 10m 0s.
- Bundle IDs not shown in the UI capture; record from the download icons on submit.

Both deliverables read in full against golden-KM05-v4.docx and grader-guidelines-task5-v4.txt before labeling.

KEY FINDING: The decider is plan item 1, the cardiorenal regimen. The two notes are otherwise near-identical and correct: both select the patient-reported draft copy, reframe the home BP as patient report, gate decisions on today's pending labs, hold metformin, assert no numeric prednisone dose, surface the dropped spironolactone/empagliflozin, add the endocrinology follow-up, and reframe the unsupported immunization claim to review-and-verify. They diverge on the held cardiorenal agents: A keeps them held and defers the staged restart (continues only the never-interrupted aspirin/atorvastatin/carvedilol and sequences the rest against labs and the cardiology/nephrology follow-ups). B advances the regimen, resuming the held agents at this visit gated on today's labs, and adds spironolactone and empagliflozin to the advance. B falls for the central trap (premature restart at the PCP visit, which the chart defers to outpatient cardiology and nephrology); A resists it.

VERDICT: A3 (A much better). Button = A++ (two plus signs).

## Justification

Preferred output: A

Both notes are thorough, source-grounded, and well-formatted, and both correctly reframe the home blood-pressure readings as patient report and gate decisions on today's pending labs. The deciding factor is plan item 1, the cardiorenal regimen, which is the task's central axis. A keeps the held agents held and defers the staged restart; B advances the regimen, resuming the held agents at this primary-care visit gated on today's labs and adding spironolactone and empagliflozin to that advance. Both cardiology and nephrology defer a staged, parameter-gated restart to outpatient follow-up and decline a restart at this visit, so B's advance is the premature restart the chart forbids. A resists the central trap; B falls for it.

Justification: Section C of the grader names premature cardiorenal restart as the central scored failure, and the home blood-pressure readings as something that may be recorded as patient report but must not be used to resume held therapy. B resumes the held agents at this visit and broadens the resumption to more agents than the draft did; A holds them and defers the restart to outpatient cardiology and nephrology. Outside item 1 the two plans are equivalent and clinically sound: patient-reported home BP, metformin held pending confirmed renal recovery, no numeric prednisone dose, anemia chronic and at baseline with no inpatient iron studies, immunizations reframed from current to review-and-verify. The gap is confined to whether the held cardiorenal agents are resumed.

Prompt adherence: Both finalize the draft into a signable note, remove every DRAFT marker including the easily-missed running page footer, preserve the letterhead, demographics, and house formatting, add a signature block, and complete the open placeholders. Tie.

Correctness: The cardiorenal action is the sole correctness failure. B resumes renally and hemodynamically sensitive GDMT at the primary-care visit against both consultants' staged-restart-deferred position, even with lab gating; A holds those agents and defers. Every other clinical decision is correct in both: patient-reported BP, metformin held, prednisone without a numeric dose, anemia chronic and at baseline, spironolactone and empagliflozin surfaced as held.

Completeness: Infection/antibiotic, AKI/CKD, cardiorenal, glycemic, steroid, anemia, functional and safety, supervision with the weekday-morning gap, OSA, follow-up including the added endocrinology, and return precautions are present in both. Neither drops a domain; A runs longer with more sourced detail.

Methodology: Both read the full chart, detect the two-copy draft and select the patient-reported version, trace doses to the MAR, medication reconciliation, and consults, and gate on pending labs. The difference is the restart judgment: A synthesizes the staged-restart-deferred guidance and holds; B reads the same guidance and advances the regimen anyway.

Quality and clarity: Comparable register and structure; both are problem-oriented, physician-ready notes with intact header and signature block. A is longer with more sourced detail; B is tighter. Neither document has formatting or readability problems.

Summary: A is preferred because B falls for the task's central designed trap, resuming the held cardiorenal agents at the primary-care visit against the chart's defer-to-outpatient guidance, while A holds them and defers the staged restart. On every other axis the two are equivalent and correct. The gap is the central restart action, which is why this is A3 rather than a narrower margin.

## Guardrails (must survive any edit)
1. The decider is item 1, hold vs advance. Do not claim both held or both advanced.
2. B's error = resuming/advancing the held cardiorenal agents at the visit; lab-gated is still a restart. A held and deferred.
3. Both are otherwise near-identical and correct (patient-reported BP, immunization reframe, endocrinology follow-up, no prednisone number). The gap is the restart action only.
4. The gap word is "much better" = A3 = A++. Not A4 (B is a single central error in an otherwise usable note, not multi-error or unusable). Not A2 (it is the central trap, not a secondary finding).
5. PL 1 of 3 required for KM05; two more on different trajectories needed.

## Submit mechanics
Select A++ (two plus signs) -> paste justification (from "Preferred output: A" through "Summary") into Comments -> Submit Preference -> confirm entry shows in submission history -> run Preference Labels AutoQC.
